



Comparison of effectiveness and safety between granules and decoction of Chinese herbal medicine: A systematic review of randomized clinical trials

Hui Luo^a, Qing Li^a, Andrew Flower^{b,**}, George Lewith^b, Jianping Liu^{a,c,*}

^a Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China

^b Center for Research on Complementary and Alternative Medicine, University of Southampton, United Kingdom

^c The National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, University of Tromsø, Tromsø N-9296, Norway

ARTICLE INFO

Article history:

Received 17 September 2011

Received in revised form 22 January 2012

Accepted 22 January 2012

Available online 9 February 2012

Keywords:

Chinese herbal medicine

Granules

Decoction

Comparison

Systematic review

Clinical trials

ABSTRACT

Background: The clinical use of Chinese herbal medicine granules is gradually increasing. However, there is still no systematic review comparing the effectiveness and safety of granules with the more traditional method of herbal decoctions.

Method: A literature search was conducted using China National Knowledge Infrastructure Databases (CNKI), Chinese Science and Technology Periodical Database (VIP), China Biomedical Database web (CBM), Wanfang Database, PubMed, and the Cochrane Library until March 10, 2011. Clinical controlled trials (CCTs) including randomized trials (RCTs) comparing the effectiveness and safety between Chinese herbal medicine granules and decoction were included. Two authors conducted the literature searches, and extracted data independently. The assessment of methodological quality of RCTs was based on the risk of bias from the Cochrane Handbook, and the main outcome data of trials were analyzed by using RevMan 5.0 software. Risk ratio (RR) or mean difference (MD) with a 95% confidence interval (CI) were used as effect measure.

Results: 56 clinical trials ($n=9748$) including 42 RCTs and 14 CCTs were included, and all trials were conducted in China and published in Chinese literature. 40 types of diseases and 15 syndromes of traditional Chinese medicine (TCM) were reported. Granules were provided by pharmaceutical companies in 13 trials. The included RCTs were of generally low methodological quality: 7 trials reported adequate randomization methods, and 2 of these reported allocation concealment. 10 trials used blinding, of which 5 trials used placebo which were delivered double blind (blinded participants and practitioners). 98.2% (55/56) of studies showed that there was no significant statistical difference between granules and decoctions of Chinese herbal medicine for their effectiveness. No severe adverse effects in either group were reported.

Conclusions: Due to the poor methodological quality of most of the included trials, it is not possible to reach a definitive conclusion whether both Chinese herbal medicine granules and decoctions have the same degree of effectiveness and safety in clinical practice, but this preliminary evidence supports the continued use of granules in clinical practice and research. Standardization of granules and further more rigorous pharmacological, toxicological and clinical studies are needed to demonstrate the equivalence with decoctions.

© 2012 Elsevier Ireland Ltd. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Background

Prolonged boiling or 'decocting' is the earliest and most popular method of preparing herbal medicines in the practice of traditional Chinese medicine (TCM). The composition of herbs within a decoction is flexible and can be revised according to the condition of a patient, defined according to TCM syndrome differentiation and treatment principles. However, decoctions have some disadvantages, such as the difficulties in ensuring quality control of the herbal ingredients, the time and inconvenience they required to prepare, the practical problems relating to their transportation and storage, the difficulty in ensuring

* Corresponding author at: Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, China, 100029. Tel.: +86 10 64286757; fax: +86 10 64286760.

** Corresponding author at: Complementary Medicine Research Unit, Dept Primary Medical Care, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton SO16 5ST, United Kingdom.

E-mail addresses: flower.power@which.net (A. Flower), jianping.li@hotmail.com (J. Liu).

adequate quality control of the herbal ingredients, and the requirement to consume a large volume of unpleasant tasting medicine. These obstacles can reduce compliance and may interfere with Chinese herbal medicine (CHM) treatment. Historically different kinds of formulation have been developed in response to these shortcomings. These include traditional preparations of *wan* (pills), *san* (powder), *gao* (ointment), *dan* (another type of pill used in TCM) and the modern formulations of granules (*ke li ji*), oral liquids, capsules, tablets, and even injections.

Since granules may retain the advantages of decoctions and also address the problems of quality control, preparation, and administration that occur with decoctions, their use has increased dramatically both within China and other Asian countries and regions. In Taiwan, Japan and South Korea research into granules began in the 1970s, and has led to rapid growth in this sector of the herbal market. In Japan, more than 400 kinds of granules have been developed, 148 Kampo granule herbal drugs were covered by National Health Insurance Fund, and 86% of Japanese medical doctors use granules in their clinical practice (Edwin Lowell and Nobuo, 2004). In South Korean, more than 300 kinds of concentrated granules have been developed and are now covered by health insurance (Zhang et al., 2000). Compared with Taiwan, Japan and South Korean, the mainland of China's research and development in this field has been relatively slower. Although Chinese herbal medicine granules were first included in the 1977 edition of Chinese Pharmacopoeia (*zhong guo yao dian*) (Yuan, 1999), these 'granules' were developed from patent medicine formulations and did not include single herbal granules that could be used for individualized prescriptions. Until 1987, the Chinese Ministry of Health required the reform of TCM formulations in order to improve their effectiveness and to ensure adequate protection for endangered Chinese medicinal plants. Therefore, after their initial production and a period of evaluation about 4 years, Chinese manufactured granules for individualized prescriptions were first produced in 1992, and the first group of herbal pharmaceutical companies producing granules were officially approved by the Chinese State Administration of TCM in 1993. Currently, Chinese pharmaceutical companies have developed more than 600 kinds of individual herb granules and 200 kinds of herbal formulae, which have been widely used in clinical practice (Jia and Zhang, 2005; Li, 2006; Ltd, 2011). Granules were covered by basic medical insurance in Beijing in April 2009.

With the development and wide use of granules, their effectiveness and safety have become an increasing focus for research. How do the effectiveness and safety of granules' compare with decoctions? Can granules be used as a substitute to traditional decoctions? There is considerable confusion and uncertainty in both herbal medicine producers and consumers in regard to these issues (Zhao, 1996; Yuan, 1999; Cheng, 2000; Xia, 2000; Li and Chen, 2010). Within a complex Chinese herbal formula, a variety of chemical reactions may occur during preparation. Differences in the detail of manufacture (boiling, desiccation and granulation) may affect dissolution rates and change the proportion of available compounds within a formula (Yuan, 1999; Zhang and Jiang, 2005; Yu et al., 2010). There is some chromatographic evidence that contents of constituents and active components in a herbal decoction may exhibit a different high-performance liquid chromatography (HPLC) fingerprint chromatogram to those found in an identical mixture of granules dissolved in boiling water (Chen et al., 2006; Ma et al., 2006). In addition, in China the price of granules is higher than dried Chinese herbs used in decoctions and this has limited the use of granules (Zhang and Jiang, 2005; Li, 2006; Liu, 2008; Li and Chen, 2010). In the West the converse is true and powders are considerably cheaper to use than decocted herbs.

In response to this confusion clinical studies comparing the effectiveness and safety of decoctions and granules have been published over the previous 3 decades, but no systematic review of these studies has been published. The aim of this current review is to examine these data to evaluate the effectiveness and safety of granules in comparison with decoctions, in order to address this confusion.

2. Materials and methods

2.1. Search strategy

A search strategy was designed to search all the available literature. We searched the Chinese National Knowledge Infrastructure Databases (CNKI) (1979–2011), the Chinese Science and Technology Periodical Database (VIP) (1989–2011), the Chinese Biomedical Database web (CBM) (1978–2011), the Wanfang Database (1985–2011), PubMed (1966–2011), and the Cochrane Library (Issue 3, 2011). All the searches ended at 10th March 2011. There was no limitation on language or publication type. The search terms included "decoction" and "granules". Two authors (Luo and Li) conducted the literature search independently. Articles were screened according to the title and then selected after abstracts were read. The full text was downloaded if the study met the inclusion criteria.

2.2. Inclusion criteria

Studies meeting the following three criteria were included in this review: (1) Type of studies: randomized controlled trials (RCTs), clinical controlled trials (CCTs). (2) Type of interventions: the study was designed to compare the effectiveness and safety of granules and decoctions, or if the clinical trial included more than two kinds of interventions, at least of which one was a decoction group and the other one was granule group. (3) The proportions of herbal medicine composition in the decoction and granules were the same.

2.3. Exclusion criteria

The following kinds of studies were excluded: (1) Multiple publications reporting the same data of patients. (2) Lack of basic information on participants or interventions. (3) Inconsistency in intervention between treatment and control group. (4) Interventions for external use.

2.4. Assessment methods

2.4.1. Searching for studies

Searching for studies was carried out by using criteria from the Cochrane Reviewers' Handbook 5.0.2 (Higgins and Green, 2009): (1) Search results from different databases were imported into the document management software Note Express 2.0; (2) Repeated and non-relevant studies were rejected by screening the title and abstract; (3) The full text of studies of potential relevance to the review were downloaded. (4) Repeated studies and publications were removed. (5) In instances of missing information the main researcher of the study was contacted for clarification. (6) Studies for inclusion were identified according to the inclusion criteria. (7) Finally a decision was made whether or not to include the study. Steps 1–5 were carried on by Luo, 6–7 steps were carried on by Luo and Li independently. They also cross checked the results with each other. Disagreements were resolved by discussion or submitting to the third researcher (Liu).

2.4.2. Methodological quality assessment

Evidence from an RCT is considered as the gold standard for therapeutic evaluation, so we specifically evaluated the methodological quality of RCTs in this review. Two authors (Luo and Li) evaluated the quality of included RCTs. Assessment of the methodological quality of RCTs was conducted in accordance with criteria from the Cochrane Reviewers' Handbook 5.0.2 (Higgins and Green, 2009). We assessed studies according to the risk of bias for each important outcome within the included trials, taking into account the adequacy of the generation of the allocation sequence, allocation concealment, blinding and outcome reporting. The quality of all the included trials was categorized as low/unclear/high risk of bias. Trials that met all the criteria were categorized as low risk of bias, those that met none of the criteria were categorized as high risk of bias, and the others were categorized as unclear risk of bias if insufficient information was available to make a judgment. Disagreements were submitted to JP Liu to resolve.

2.4.3. Data extraction and analysis

A data extraction form was designed by all the authors. Two authors (Luo and Li) extracted the data independently. Data was inputted into Microsoft Excel. Items in the form included (1) citations (author, title, journal, year, issue, volume, and page); (2) methodological character of trials; (3) participants (sample size, disease); (4) the nature of the interventions; (5) outcome measures; (6) a summary of results; (7) adverse effects; and (8) health economic outcomes.

The main outcomes data of the trials were analyzed by using RevMan 5.0 software. The efficacy measure was risk ratio (RR) with a 95% confidence interval (CI) for dichotomous data or mean difference (MD) with a 95% CI for continuous data. Meta-analysis was to be used if the trials had a good homogeneity of study design, participants, interventions, control, and outcome measures.

3. Results

3.1. Basic information of studies

After a primary search of 6 electronic databases, 700 citations were identified, 28 of which were identified from PubMed and Cochrane Library. However the majority of these were excluded due to their obvious ineligibility after reading the title/abstract or their repeated mention in different databases. 87 studies were included in the initial analysis. After reading the full text of each article, 56 trials met the inclusion criteria and were included in the final review, including 42 RCTs, 14 CCTs (Fig. 1). All the included studies were published in Chinese. A study identified in the Cochrane Library met the inclusion criteria but the full text was not available, therefore, the full article was downloaded from a Chinese Journal database according to its' citation (Liang and Li, 1995).

9748 patients were involved in the included 56 trials. The mean sample size of trials was 174, the minimum was 30 and maximum was 1982. All the trials were carried out in China. There was a diverse distribution of diseases or TCM syndromes, with 40 diseases diagnosed according to modern medicine and 15 syndromes diagnosed according to TCM. Participants in some trials were diagnosed by a combination of modern medicine and TCM. The majority of interventions (52/56) were oral use; interventions in 4 trials used enemas (Pan et al., 2005; Lv et al., 2007; Zhou et al., 2009; Xie and Li, 2010). More details of the trials are presented in Table 1.

According to our pre-defined methodological quality criteria, no trial could be considered as having a low risk of bias, and the majority (76.2%, 32/42) of the included RCTs were evaluated as having a

high risk of bias. None of the trials reported sample size calculation; 7 trials (Liang and Li, 1995; Lv et al., 2003; Liu et al., 2005; Kuang et al., 2008; Lu et al., 2008; Wei et al., 2009a,b) described adequate randomization procedures (such as use of a random number table or computer generated random numbers), 2 of these (Lu et al., 2008; Wei et al., 2009b) reported allocation concealment; 10 trials (Xu et al., 1998; Liu et al., 2005; Lv et al., 2007; Lu et al., 2008; Kuang et al., 2008; Huang and Zhu, 2009; Liao et al., 2009; Wang et al., 2009; Wei et al., 2009b; Xie and Li, 2010) mentioned blinding, of which 5 (Liu et al., 2005; Lu et al., 2008; Wang et al., 2009; Wei et al., 2009a; Huang and Zhu, 2009) reported that they used a placebo control. Other than for Liu's trial, placebos made from granules and decoctions were provided by pharmaceutical companies in the other 5 trials. In Huang, Liu, Lu and Wei's trials, matched placebos were used to blind participants and practitioners; that is, in intervention group, patients received both real granules and placebo decoctions, while patients in control group received both real decoctions and placebo granules, which made the blind feasible. Moreover, both placebo decoction and granules were indistinguishable from the real treatment with respect to color, smell and packaging. In Lv's trial (Lv et al., 2007), granules and decoction were prepared using the same packaging in the form of dark liquid, for which the color and smell were the same. All the packaging work was prepared in the hospital pharmacy. When these packages arrived at participants and practitioners location, they were blind to the intervention. So there was no need to use a placebo in this study. The other 4 trials did not report any details on how blinding was achieved. None of trials included a blinded assessor. Five trials (Liu et al., 2005; Lv et al., 2007; Lu et al., 2008; Zhou et al., 2008; Wei et al., 2009b) reported the number of dropouts, but none of them used an intention-to-treat analysis.

Only 3 trials (Huang and Zhu, 2009; Wang et al., 2009; Wei et al., 2009b) mentioned that their research used a non-inferiority study design to compare the effectiveness of decoction and granules.

3.2. Effectiveness and safety evaluation

3.2.1. Selection of outcome measure

Due to the diversity of diseases in the included trials, the outcomes measures were similarly diverse. The majority of trials used complex outcomes measures containing symptoms, signs, and laboratory indexes, to evaluate the effectiveness of interventions. However the outcomes were also frequently aggregated and divided into four basic categories of therapeutic response: clinical remission (or clinical completely remission), marked effect, effective, and ineffective. The definitions of these were similar in all the trials. For example, ineffective was defined as "there is no significant difference or deterioration in symptoms, signs, or laboratory indices before and after treatment"; the effective was defined as "there is an improvement in symptoms, signs, or laboratory indices after treatment". Marked effective was defined as "there is a significant improvement in symptoms, signs, or laboratory indices after treatment"; and the clinical remission was defined as "the clinical symptoms and signs disappeared, and laboratory indices return to normal after treatment" (Liu et al., 2005; Lv et al., 2007; Lu et al., 2008; Zhou et al., 2008; Wei et al., 2009b). In addition, some trials reported disease specific outcomes. For example, an RCT on uterine fibroids (Yang et al., 2008) reported the change of uterine volume.

3.2.2. Estimate effect of decoction and granules

45 trials reported outcomes as dichotomous data, so RR was used in their evaluation. 11 trials reported laboratory outcomes or outcomes providing continuous data, so MD with a 95% CI was used. The results showed that, with the exception of 1 RCT

Table 1
Characteristics of studies.

Study	Design	Fund	Sample size	Granule source	Disease and TCM diagnosis	Groups	Formula and its component	Medicine dosage (G vs D)	Decoction preparation	Outcome measure
Tan and Tan (2010)	CCT	N	150	PC (U)	Cervical spondylosis	3	Self-made formula (S)	U	U	ER, cost-effect analysis
Yang et al. (2010)	RCT	Y	58	U	Chronic atrophic gastritis (deficiency of stomach <i>yin</i>)	3	Self-made formula (S)	=	U	ER, improvement from gastroscopy and pathology
Qin (2010)	RCT	N	63	PC (U)	Essential hypertension	3	<i>tianma gouteng yin</i> (C)	U	U	blood pressure, symptoms of RCM, blood biochemistry
Xie and Li (2010)	RCT	N	101	PC (U)	Ulcerative colitis (<i>yang</i> deficiency of spleen and kidney)	2	<i>sishen wan</i> (S)	=	R	ER, TCM syndrome scores, Sutherland index
Liao et al. (2009)	RCT	Y	60	PC (F)	Stroke recovery (<i>qi</i> deficiency and blood stasis)	2	<i>buyang huanwu tang</i> (C)	1/3	R	ER, TCM syndrome scores
Wei et al. (2009b)	RCT	Y	153	PC (F)	Chronic gastritis, functional dyspepsia (stomach deficiency)	3	<i>liangfu wan</i> (S)	U	R	ER
Huang and Zhu (2009)	RCT	Y	116	PC (F)	Acute and chronic bronchitis (phlegm and heat)	2	Self-made formula (C)	U	R	ER
Zhou et al. (2009)	RCT	N	40	U	Chronic pelvic inflammation	2	Self-made formula (C)	=	R	ER
Chen et al. (2009)	RCT	N	105	PC (F)	Chronic gastritis	2	Self-made formula (S)	=	R	ER, symptoms score
Wei et al. (2009a)	RCT	N	130	PC (F)	Chronic kidney disease stage of 4 or 5 (deficiency of <i>qi</i> and blood, wetness internal)	3	Self-made formula (S)	<	R	scores of symptoms and SGA, function indexes of nutritional, renal and hematopoietic
Zhao et al. (2009)	RCT	N	100	PC (U)	Acute bronchitis children (wind-heat invading lung)	2	Self-made formula (S)	=	U	ER, TCM syndrome
Xiang et al. (2009)	CCT	Y	335	PD	Chronic hepatitis B	2	Self-made formula (S)	=	R	liver function, ER
Zhang and Cai (2009)	RCT	N	65	PC (F)	Acute sinusitis (gallbladder heat stagnation)	2	Self-made formula (S)	U	U	ER
Wang et al. (2009)	RCT	Y	88	PC (U)	Papular urticaria (wind-heat)	3	Self-made formula (S)	U	R	ER
Zhou et al. (2008)	RCT	N	80	PC (F)	Insomnia	2	Self-made formula (S)	=	R	ER, Pittsburgh Sleep Quality Index (PSQI), TCM syndrome scores
Lu et al. (2008)	RCT	Y	150	PC (U)	Diarrhea (cold wetness)	3	<i>huoxiang zhengqi san</i> (S)	=	R	ER, improvement of TCM symptoms
Yang et al. (2008)	RCT	N	180	PC (U)	Hysteromyoma /fibroids	3	Self-made formula (S)	U	U	volume of uterine fibroids, ER
Li et al. (2008)	RCT	N	50	PC (U)	Infantile anorexia (spleen-stomach disharmony)	2	Unclear (S)	=	U	ER, symptoms score, weight, intake per date, urinary excretion rate of xylose
Kuang et al. (2008)	RCT	Y	60	PC (F)	Genital herpes (damp-heat)	3	<i>longdan xiegan tang</i> (S)	U	R	score of symptoms, ER
Yang and Liu (2007)	CCT	N	68	PC (F)	Sinusitis	2	Self-made formula (S)	U	U	ER
Lv et al. (2007)	RCT	N	60	PC (F)	End stage liver failure	2	Self-made formula (S)	1/3	R	ER, TCM syndrome scores, blood ammonia, Endotoxin
Zeng et al. (2006)	RCT	N	60	U	Acute bronchitis (lung <i>qi</i> obstruction, retention of fluid)	2	<i>xiaoqinglong tang</i> (S)	U	R	ER, improvement of TCM symptoms
Zhang et al. (2006)	RCT	N	173	PD	Angina pectoris (deficiency of <i>qi</i> and <i>yin</i>)	4	<i>zhigancao tang</i> (S)	=	R	ER, electrocardiogram
Feng et al. (2005)	RCT	N	80	PC (F)	Acute urinary tract infection (damp-heat)	2	<i>bazheng san</i> (S)	=	R	ER, average time of take effect, daily cost
Liu et al. (2005)	RCT	N	648	U	Pregnant women	3	Lithospermum (S)	=	R	rate of complete abortion, average time of bleeding

Table 1 (Continued)

Study	Design	Fund	Sample size	Granule source	Disease and TCM diagnosis	Groups	Formula and its component	Medicine dosage (G vs D)	Decoction preparation	Outcome measure
Pan et al. (2005)	RCT	N	153	PC (U)	Chronic prostatitis	3	Self-made formula (S)	=	R	ER, TCM syndrome scores
Guo and Zhao (2004)	RCT	N	82	PD	Herpes zoster (damp-heat)	2	Self-made formula (S)	=	R	ER, time of recovery
Sun (2004)	RCT	N	195	PC (U)	Psoriasis vulgaris	3	Self-made formula (S)	<	R	ER
Li (2003)	RCT	N	120	U	Acute tonsillitis, upper respiratory tract infection (exogenous wind-heat)	2	Self-made formula (S)	=	R	ER
Peng et al. (2003)	RCT	N	30	PD	Viral hepatitis A (damp-heat)	2	Self-made formula (S)	U	R	Recovery dates of disease, recovery dates of ALT and TBIL (d)
Lv et al. (2003)	RCT	Y	120	PC (U)	Primary osteoporosis	2	Self-made formula (S)	=	U	ER, bone mineral density, improvement and remission of low back pain
Zhai (2003)	RCT	N	100	PC (U)	Cold (wind-heat)	2	Self-made formula (S)	=	R	cure rate
Sun et al. (2003)	RCT	N	121	PC (U)	Primary gout hyperuricemia	2	Self-made formula (S)	=	R	ER, uric acid
Qian et al. (2003)	CCT	N	138	PC (U)	Post-chemotherapeutic leukopenia	3	Self-made formula (S)	=	U	cases of post-chemotherapeutic leukopenia
Zhang et al. (2002)	RCT	N	60	PC (U)	Influenza	2	Modified <i>chaihu guizhi tang</i> (S)	=	R	ER, symptoms improvement time
Yu et al. (2002)	RCT	N	100	PC (U)	Deficiency of spleen <i>qi</i>	2	<i>xiangsha liujunzi tang</i> (S)	1/2	U	ER, TCM syndrome scores
Lin et al. (2001)	CCT	Y	187	U	Eczema	3	Self-made formula (S)	<	U	ER
Hu and Wang (2000)	CCT	N	1982	PC (U)	Headache, insomnia, nervous disorders, hyperthyroidism and breast fibrosis	2	Unclear (S)	1/2~2/3	P	ER
Bei and Xiong (2000)	RCT	N	132	PC (U)	Four syndromes of TCM	2	<i>pingwei san</i> , <i>sangju yin</i> , <i>sanren tang</i> , <i>xiaoyao san</i> (C)	=	U	ER
Hu and Zeng (2000)	CCT	Y	131	PC (U)	<i>shaoyang</i> syndrome (upper respiratory tract infection, acute and chronic gastritis, gastric ulcer, hepatitis)	2	<i>xiaochaihu tang</i> (S)	=	R	ER
Qi et al. (1999)	RCT	N	1200	U	Coronary heart disease, hypertension, type 2 diabetes	2	Self-made formula (C)	=	U	ER, TCM syndrome scores, electrocardiogram, blood glucose, urine glucose, blood lipid and hematological indexes
Cheng and Zhu (1999)	RCT	N	60	U	Stomach pain (<i>qi</i> stagnation)	2	<i>chaihu shugan san</i> (S)	=	R	ER, improvement from gastroscop
Li et al. (1999)	CCT	N	200	PD	Cough (exogenous cold- retention of fluid)	2	<i>xiaoqinglong tang</i> (S)	=	U	ER, dates of cough remission
Zhou et al. (1999)	RCT	N	80	PD	ankylosing spondylitis	3	self-made formula (S)	1/4	R	ER, symptoms, signs and laboratory examination indexes
Zhang (1998)	CCT	N	100	PC (F)	Non-acute cholecystitis	2	Self-made formula (S)	=	R	ER, time of symptoms improvement
Xu et al. (1998)	RCT	N	93	U	Peptic ulcer, chronic gastritis	3	<i>buzhong yiqi tang</i> (unclear)	U	U	ER
Du and Xie (1998)	RCT	N	90	PD	Exogenous fever	3	<i>yinqiao san</i> (S)	=	R	ER
Wang et al. (1998)	CCT	N	60	PC (U)	Wind-cold-wet syndrome (cold, vomiting, diarrhea)	2	<i>huoxiang zhengqi san</i> (S)	=	R	ER, improvement of vomiting, abdominal pain, diarrhea and fever, blood, stool

Table 1 (Continued)

Study	Design	Fund	Sample size	Granule source	Disease and TCM diagnosis	Groups	Formula and its component	Medicine dosage (G vs D)	Decoction preparation	Outcome measure
Qiu et al. (1998)	CCT	N	82	U	Chronic hepatitis B (spleen deficiency and dampness-heat with blood stasis)	3	Self-made formula (unclear)	U	U	ER, negative conversion rate of HBsAg and HBV-DNA, liver function
Gao et al. (1998)	CCT	N	62	U	Acute hepatitis E	2	Self-made formula (S)	U	U	ER, improvement of symptoms and signs, liver function, serum viral markers
Zhang and Huang (1996)	RCT	N	100	U	Damp stagnation	2	huoxiang zhengqi san (S)	=	R	ER
Shao (1996)	RCT	N	62	U	Stomach pain of qi stagnation	2	chaihu shugan san (S)	=	R	ER, improvement of symptoms, laboratory examination
Liang and Li (1995)	RCT	Y	60	PD	Acute cerebral hemorrhage of gan yang hua feng	2	Self-made formula (C)	=	R	ER, improvement of symptoms
Zhu et al. (1995)	CCT	N	373	PD	yin deficiency of kidney	3	Series of liuwei dihuang wan formula (C)	=	R	ER, laboratory examination
Tian et al. (1985)	CCT	N	167	PC (F)	Stomach pain	2	Self-made formula (C)	U	U	ER
Xu (1980)	CCT	N	135	U	Rheumatoid arthritis	5	Tripterygium (S)	<	U	ER

G: granule; D: decoction; RCT: randomized controlled trial; CCT: control clinical trial; Y: yes; N: no; PC: pharmaceutical company; PD: pharmacy department of setting hospital; U: unclear; F: free of charge; S: single; C: compound; R: prepared by researchers; P: prepared by patients; ER: effective rate; TCM: traditional Chinese medicine.

(Xie and Li, 2010) that reported the superiority of granules over a decoction when *sishen wan* was used as an enema for moderate colitis (MD: 0.71; 95% CI: [0.59, 0.83]), the results in all the trials showed no significant difference between the decoction and granule using groups. These results are presented in Table 2.

3.2.3. Adverse effects

23 trials (Xu, 1980; Liang and Li, 1995; Shao, 1996; Zhang and Huang, 1996; Xu et al., 1998; Qi et al., 1999; Zhou et al., 1999; Hu

and Zeng, 2000; Hu and Wang, 2000; Lin et al., 2001; Lv et al., 2003, 2007; Qian et al., 2003; Sun et al., 2003; Liu et al., 2005; Lu et al., 2008; Kuang et al., 2008; Liao et al., 2009; Wang et al., 2009; Wei et al., 2009a,b; Huang and Zhu, 2009; Xie and Li, 2010) reported mild adverse effects; no severe adverse effects were reported in the studies. No statistical differences were found in the rate of mild adverse effects occurring between decoction and granule groups. The review demonstrated that Chinese herbal medicine granules were safe.




Fig. 1. Selection of clinical trials comparing granules and decoction. CNKI: China National Knowledge Infrastructure Databases; VIP: Chinese Science and Technology Periodical Database; CBM: Chinese Biomedical Literature Database; Wanfang: Wanfang database; RCTs: randomized controlled trials; CCTs: controlled clinical trials.

Table 2
Effect estimates of the included studies.

Study	Intervention (G vs D)	Effect index	RR/MD	95%CI
Tan and Tan (2010)	Self-made granules (n = 50) vs self-made decoction (n = 50)	Effective rate	0.98	[0.86, 1.11]
Yang et al. (2010)	Self-made granules (n = 19) vs self-made decoction (n = 18)	Effective rate	1.07	[0.83, 1.39]
Qin (2010)	<i>tianma gouteng yin</i> granules (n = 22) vs <i>tianma gouteng yin</i> decoction (n = 18)	Effective rate	0.98	[0.79, 1.21]
Xie and Li (2010)	<i>sishen wan</i> granules (n = 58) vs <i>sishen wan</i> decoction (n = 43)	Sutherland index	0.71 (MD)	[0.59, 0.83]
Liao et al. (2009)	<i>buyang huanwu tang</i> granules (n = 30) vs <i>buyang huanwu tang</i> decoction (n = 30)	Effective rate	1.14	[0.87, 1.49]
Wei et al. (2009a)	<i>liangfu wan</i> granules (n = 52) vs <i>liangfu wan</i> decoction (n = 51)	Effective rate	1.02	[0.91, 1.15]
Huang and Zhu (2009)	<i>qingjin tangjiang</i> granules + placebo of decoction (n = 58) vs <i>qingjin tangjiang</i> decoction + placebo of granules (n = 58)	Effective rate	1.00	[0.89, 1.12]
Zhou et al. (2009)	Self-made granules enema (n = 20) vs self-made decoction enema (n = 20)	Effective rate	1.11	[0.93, 1.31]
Chen et al. (2009)	Self-made granules (n = 55) vs self-made decoction (n = 50)	Effective rate	1.01	[0.90, 1.13]
Wei et al. (2009a)	Self-made granules (n = 50) vs self-made decoction (n = 38)	SCr (umol/L); BUN (mmol/L)	SCr: -13.64(MD); BUN: 0.34(MD)	SCr: [-41.80, 14.52]; BUN: [-1.49, 2.17]
Zhao et al. (2009)	Self-made granules (n = 43) vs self-made decoction (n = 43)	Effective rate	0.98	[0.89, 1.07]
Xiang et al. (2009)	Self-made granules (n = 105) vs self-made decoction (n = 127)	ALT (U/L), AST (U/L), TBil (μmol/L)	ALT: 1.07 (MD); AST: -1.67(MD); TBil: -0.81(MD)	ALT: [-4.82, 6.96]; AST: [-8.36, 5.02]; TBil: [-8.04, 6.42]
Zhang and Cai (2009)	Self-made granules (n = 35) vs self-made decoction (n = 30)	Effective rate	1.04	[0.93, 1.16]
Wang et al. (2009)	Self-made granules + placebo of decoction (n = 26) vs self-made decoction + placebo of granules (n = 27)	Effective rate	1.08	[0.95, 1.22]
Zhou et al. (2008)	Self-made granules (n = 36) vs self-made decoction (n = 36)	Pittsburgh Sleep Quality Index (PSQI)	-0.24(MD)	[-1.85, 1.37]
Lu et al. (2008)	<i>huoxiang zhengqi san</i> granules + placebo of decoction (n = 36) vs <i>huoxiang zhengqi san</i> decoction + placebo of granules (n = 36)	Effective rate	1.00	[0.89, 1.13]
Yang et al. (2008)	Self-made granules (n = 40) vs self-made decoction (n = 100)	Volume of uterine fibroids (cm ³)	-0.66 (MD)	[-6.13, 4.81]
Li et al. (2008)	Self-made granules (n = 25) vs self-made decoction (n = 25)	Effective rate	1.16	[0.89, 1.51]
Kuang et al. (2008)	<i>longdan xiegan tang</i> granules (n = 20) vs <i>longdan xiegan tang</i> decoction (n = 20)	Effective rate	1.00	[0.81, 1.23]
Yang and Liu (2007)	Self-made granules (n = 38) vs self-made decoction (n = 30)	Cure rate	1.04	[0.67, 1.61]
Lv et al. (2007)	Self-made granules (n = 20) vs self-made decoction (n = 22)	Blood ammonia, Endotoxin	NH3: 3.19 (MD); ETM: -0.00 (MD).	NH3: [-9.92, 16.30]; ETM: [-0.02, 0.02]
Zeng et al. (2006)	<i>xiaoqinglong tang</i> granules (n = 30) vs <i>xiaoqinglong tang</i> decoction (n = 30)	Cure rate	1.11	[0.53, 2.34]
Zhang et al. (2006)	<i>zhigancao tang</i> granules (n = 43) vs <i>zhigancao tang</i> decoction (n = 43)	ECG improvement rate	1.19	[0.88, 1.62]
Feng et al. (2005)	<i>bazheng san</i> granules (n = 42) vs <i>bazheng san</i> decoction (n = 38)	Effective rate	1.03	[0.92, 1.16]
Liu et al. (2005)	<i>Lithospermum</i> granules (n = 217) vs <i>lithospermum</i> decoction (n = 221)	Complete abortion rate	1.00	[0.97, 1.03]
Pan et al. (2005)	Self-made granules enema (n = 50) vs self-made decoction enema (n = 53)	Effective rate	1.03	[0.91, 1.16]
Guo and Zhao (2004)	Self-made granules (n = 42) vs self-made decoction (n = 40)	Cure rate	1.06	[0.78, 1.44]
Sun (2004)	Self-made granules (n = 104) vs self-made decoction (n = 35)	Effective rate	0.98	[0.89, 1.08]
Li (2003)	Self-made granules (n = 60) vs self-made decoction (n = 60)	Effective rate	1.00	[0.91, 1.10]

Table 2 (Continued)

Study	Intervention (G vs D)	Effect index	RR/MD	95%CI
Peng et al. (2003)	Self-made granules (n = 30) vs self-made decoction (n = 30)	Recovery dates of ALT and TBIL (d)	ALT: 1.01 (MD); TBIL: -0.48 (MD)	ALT: [-36.74, 38.76]; TBIL: [-37.52, 36.56]
Lv et al. (2003)	Self-made granules (n = 64) vs self-made decoction (n = 56)	Bone mineral density (g/cm ²)	0.01 (MD)	[-0.04, 0.06]
Zhai (2003)	Self-made granules (n = 50) vs self-made decoction (n = 50)	Cure rate	1.02	[0.92, 1.14]
Sun et al. (2003)	Self-made granules (n = 40) vs self-made decoction (n = 41)	Uric acid (μmol/L)	3.85 (MD)	[-33.46, 41.16]
Qian et al. (2003)	Self-made granules (n = 50) vs self-made decoction (n = 46)	Rate of post-chemotherapeutic leukopenia	0.95	[0.69, 1.31]
Zhang et al. (2002)	Modified <i>chaihu guizhi tang</i> granules (n = 30) vs modified <i>chaihu guizhi tang</i> decoction (n = 30)	Defervescence time (h)	1.64 (MD)	[-1.80, 5.08]
Yu et al. (2002)	<i>xiangsha liujunzi tang</i> granules (n = 50) vs <i>xiangsha liujunzi tang</i> decoction (n = 50)	Effective rate	1.04	[0.93, 1.17]
Lin et al. (2001)	Self-made granules (n = 63) vs self-made decoction (n = 65)	Cure rate	0.88	[0.63, 1.25]
Hu and Wang (2000)	Self-made granules (n = 803) vs self-made decoction (n = 1179)	Effective rate	Headache: 0.99 insomnia: 0.98 nervous disorders: 0.99 hyperthyroidism: 1.02 breast fibroids: 1.00	Headache: [0.96, 1.03] insomnia: [0.94, 1.02] nervous disorders: [0.95, 1.02] hyperthyroidism: [0.97, 1.09] breast fibroids: [0.95, 1.07]
Bei and Xiong (2000)	Self-made granules (n = 66) vs self-made decoction (n = 66)	Effective rate	0.98	[0.88, 1.10]
Hu and Zeng (2000)	<i>xiaochaihu tang</i> granules (n = 68) vs <i>xiaochaihu tang</i> decoction (n = 63)	Effective rate	0.99	[0.91, 1.07]
Qi et al. (1999)	Self-made granules (n = 800) vs self-made decoction (n = 400)	Effective rate	Coronary heart disease: 1.03 hypertension: 1.02 type 2 diabetes: 1.02	Coronary heart disease: [0.97, 1.10] hypertension: [0.96, 1.08] type 2 diabetes: [0.97, 1.08]
Cheng and Zhu (1999)	<i>chaihu shugan san</i> granules (n = 68) vs <i>chaihu shugan san</i> decoction (n = 63)	Effective rate	1.24	[0.94, 1.63]
Li et al. (1999)	<i>xiaoqinglong tang</i> granules (n = 100) vs <i>xiaoqinglong tang</i> decoction (n = 100)	Cough remission time (d)	-0.10 (MD)	[-0.33, 0.13]
Zhou et al. (1999)	Self-made granules (n = 42) vs self-made decoction (n = 18)	Effective rate	1.01	[0.88, 1.15]
Zhang (1998)	Self-made granules (n = 50) vs self-made decoction (n = 50)	Effective rate	1.05	[0.89, 1.23]
Xu et al. (1998)	<i>buzhong yiqi tang</i> granules (n = 33) vs <i>buzhong yiqi tang</i> decoction (n = 32)	Effective rate	1.01	[0.82, 1.24]
Du and Xie (1998)	<i>yinqiao san</i> granules (n = 30) vs <i>yinqiao san</i> decoction (n = 30)	Effective rate	1.00	[0.91, 1.10]
Wang et al. (1998)	<i>huoxiang zhengqi san</i> granules (n = 30) vs <i>huoxiang zhengqi san</i> decoction (n = 30)	Effective rate	1.00	[0.94, 1.07]
Qiu et al. (1998)	self-made granules (n = 33) vs self-made decoction (n = 34)	Negative conversion rate of HBsAg and HBV-DNA	HBsAg: 0.92 HBV-DNA: 1.04	HBsAg: [0.53, 1.60] HBV-DNA: [0.59, 1.83]
Gao et al. (1998)	Self-made granules (n = 31) vs self-made decoction (n = 31)	Cure rate	2.00	[0.19, 20.93]
Zhang and Huang (1996)	<i>huoxiang zhengqi san</i> granules (n = 50) vs <i>huoxiang zhengqi san</i> decoction (n = 50)	Effective rate	1.02	[0.93, 1.12]
Shao (1996)	<i>chaihu shugan san</i> granules (n = 31) vs <i>chaihu shugan san</i> decoction (n = 31)	Effective rate	1.07	[0.94, 1.22]
Liang and Li (1995)	Self-made granules (n = 30) vs self-made decoction (n = 30)	Hematoma absorption rate	0.99	[0.78, 1.25]
Zhu et al. (1995)	<i>liuwei dihuang wan</i> granules (n = 41) vs <i>liuwei dihuang wan</i> decoction (n = 41)	Effective rate	1.00	[0.95, 1.05]
Tian et al. (1985)	Self-made granules (n = 101) vs self-made decoction (n = 66)	Effective rate	1.01	[0.97, 1.04]
Xu (1980)	Tripterygium granules (n = 5) vs tripterygium decoction (n = 75)	Effective rate	0.67	[0.33, 1.38]

G: granule; D: decoction; RR: risk ratio; MD: mean difference; CI: confidence interval.

3.3. Characteristic of interventions

3.3.1. Arms of interventions

The numbers of treatment arms in the trials can be seen in Table 1. 62.5% (35/56) of the trials had two arms (granules and decoction); 33.9% (19/56) had three arms; 3.5% (2/56) had four or five arms. Besides granules and decoction, the interventions included placebo, western medicine, other Chinese herbal medicines, and waiting list controls. In some trials, all the participants used conventional western medicines.

3.3.2. Formulae used in interventions

20 trials researched traditional CHM formulas, including *tianma gouteng yin* (Qin, 2010), *sishen wan* (Xie and Li, 2010), *buyang huanwu tang* (Liao et al., 2009), *liangfu wan* (Wei et al., 2009b), *huoxiangzhengqi san* (Zhang and Huang, 1996; Wang et al., 1998; Lu et al., 2008), *longdan xiegan tang* (Kuang et al., 2008), *xiaoqinglong tang* (Li et al., 1999; Zeng et al., 2006), *zhigancao tang* (Zhang et al., 2006), *bazheng san* (Feng et al., 2005), *chaihui guizhi tang* (Zhang et al., 2002), *xiangsha liujunzi tang* (Yu et al., 2002), *xiaochaihu tang* (Hu and Zeng, 2000), *chaihui Shugan san* (Shao, 1996; Cheng and Zhu, 1999), *buzhong yiqi tang* (Xu et al., 1998), *yingqiao san* (Du and Xie, 1998), and *liuwei dihuang wan* (Zhu et al., 1995). Another 38 trials researched self-made formulas, of which 2 trials were single herbs: *lithospermum (zicao)* (Liu et al., 2005) and *tripterygium (leigongteng)* (Xu, 1980).

3.3.3. Sources of granules

According to the studies, granules were mainly sourced from pharmaceutical companies and pharmacy departments in hospitals. Sources of granules in 33 trials were pharmaceutical manufacturers in China, all of whom were authorized to produce granules. 13 trials stated that granules were provided by pharmaceutical companies free of charge, while 20 trials reported their granules were from pharmaceutical companies, but the authors did not specify whether their granules were free of charge. To evaluate whether granules provided and funded by pharmaceutical companies could be an important source of bias in this review, we analyzed the results of the 13 relevant trials, and found that there were no significant differences in mean outcome related to the provider or funder of the products being evaluated. The data from this subgroup was consistent with the overall results of the 56 included trials. 9 trials reported that their granules were made by the pharmacy departments in their own hospitals. 14 trials did not report the source of granules. Details on sources of granules are presented in Table 1.

3.3.4. Dosage and preparation of granules and decoction

In 32 trials (Liang and Li, 1995; Zhu et al., 1995; Shao, 1996; Zhang and Huang, 1996; Zhang, 1998; Du and Xie, 1998; Wang et al., 1998; Cheng and Zhu, 1999; Qi et al., 1999; Li et al., 1999, 2008; Bei and Xiong, 2000; Hu and Zeng, 2000; Zhang et al., 2002, 2006; Li, 2003; Lv et al., 2003; Qian et al., 2003; Sun et al., 2003; Zhai, 2003; Guo and Zhao, 2004; Liu et al., 2005; Feng et al., 2005; Pan et al., 2005; Lu et al., 2008; Zhou et al., 2008, 2009; Chen et al., 2009; Xiang et al., 2009; Zhao et al., 2009; Xie and Li, 2010; Yang et al., 2010), the dosage of granules was equivalent to the decoction; in 9 trials (Xu, 1980; Zhou et al., 1999; Hu and Wang, 2000; Lin et al., 2001; Yu et al., 2002; Sun, 2004; Lv et al., 2007; Liao et al., 2009; Wei et al., 2009a), the dosage of granules was 1/4–2/3 of that of the decoction; another 15 trials (Tian et al., 1985; Gao et al., 1998; Qiu et al., 1998; Xu et al., 1998; Peng et al., 2003; Zeng et al., 2006; Yang and Liu, 2007; Kuang et al., 2008; Yang et al., 2008; Zhang and Cai, 2009; Huang and Zhu, 2009; Wang et al., 2009; Wei et al., 2009b; Qin, 2010; Tan and Tan, 2010) did not report whether the dosage

of granules were equivalent to the decoction. Details on dosage are presented in Table 1.

2 trials (Qiu et al., 1998; Xu et al., 1998) did not report on the preparation of granules; granules in 9 trials (Tian et al., 1985; Liang and Li, 1995; Zhu et al., 1995; Qi et al., 1999; Bei and Xiong, 2000; Huang and Zhu, 2009; Liao et al., 2009; Zhou et al., 2009; Qin, 2010) were patent medicine granules, which involved the preparation of a traditional decoction of a formula of individual herbs that was then concentrated, dried and extracted to produce herbal granules (Ltd Jiangyin Tianjiang Pharmaceutical Co., 2011); In another 45 trials, the preparation of granules comprised aggregated mixtures of different single herbal granules for individualized prescription. All the individual granules had been prepared in advance by pharmaceutical companies or pharmacy departments of hospitals. In the trials, individual herb granules were formulated to match the decoction, and then mixed with boiling water for a few minutes, without the protracted boiling process that characterizes decoctions. Details on this issue are presented in Table 1.

Standardization of interventions is usually required in clinical trials. The method of CHM preparation in the decoction group (control group) should also be identical for each participant in a TCM clinical trial in order to reduce the performance bias and to compare and evaluate the effect between the decoction and other control treatments. In this review, 35 included trials used standardized methods of preparation reported by researchers, 1 trial reported that the decoction was prepared by the patients themselves, 20 trials did not report any information about preparation of the decoction (Table 1).

3.4. Sources of funding

12 trials (Liang and Li, 1995; Hu and Zeng, 2000; Lin et al., 2001; Lv et al., 2003; Kuang et al., 2008; Lu et al., 2008; Huang and Zhu, 2009; Liao et al., 2009; Wang et al., 2009; Wei et al., 2009b; Xiang et al., 2009; Yang et al., 2010) reported that they were supported by research funding from central and local government. The other 44 trials did not mention sources of funding. None of the trials reported funding from other organizations or pharmaceutical companies.

3.5. Health economic evaluation

3 trials (Hu and Wang, 2000; Feng et al., 2005; Tan and Tan, 2010) reported health economic outcomes; all the trials showed that the price of granules in China is currently higher than that of decoctions by between 16.61% and 312%.

4. Discussion

4.1. Analysis of effectiveness and safety

The results of this review suggest that there is no significant difference in effectiveness and safety between Chinese herbal medicine granules and decoctions.

Meta-analysis could not be employed due to the inconsistency and heterogeneity of study design, participants, diseases, interventions, controls, and outcome measures; nearly all the trials (98.2%) reported no difference in outcomes between granules and decoctions, and the remaining single trial's results showed the superiority of granules over decoction. We evaluated the safety reports from the granules: no serious adverse effects were reported in the studies. No statistical differences were found in the rate of mild adverse effects occurring between the decoction and granule groups.

4.2. Limitation of the systematic review

4.2.1. Methodological quality and design of included studies

The methodological quality of the included RCTs was poor. The designs of the majority of trials were also problematic. Only 3 trials mentioned that their research used a non-inferiority study designs to compare the effectiveness of decoction and granules. It seemed that most researchers lacked knowledge of the appropriate clinical research methodology. This was particularly apparent when comparing the effectiveness of a new herbal drug versus a controlled herbal drug of known and proven effectiveness. In this situation most researchers publishing in this field were still using a conventional clinical trial design and inappropriate statistical methods for significance testing. They did not apply methods used for non-inferiority, equivalence and superiority within their trial designs. This means the results of this systematic review should be interpreted with caution.

4.2.2. Potentially publication bias

None of the trials reported negative or non equivalence outcome. A greater than 98% rate of equivalence seems a little too good to be true and may be a reflection of publication bias in this systematic review. Although we searched the trials as systematically and comprehensively as possible, it seemed such publication bias was inevitable. This phenomenon maybe related to a reluctance to publish negative or conflicting data.

4.2.3. Declaring potential conflicts of interest

78.6% (44/56) of trials did not report exactly how their trials had been funded; 30.4% (17/56) of trials did not report the source of granules. 58.9% (33/56) of trials mentioned that they used granules from pharmaceutical companies, of which 60.6% (20/33) failed to report whether the granules were provided free by pharmaceutical companies. The publication of a trial has a direct relationship with trial funding and trials supported by companies are more likely to report positive results than those supported by government or other academic organizations (Liu, 2009). Consequently there maybe some risk of bias for some included trials in this review which did not report these potential conflicts of interest.

4.2.4. Inconsistency of dosages between granules and decoction

The dosages between granules and decoction were the same in 57.1% (32/56) of trials; the dosages of granules was lower than those of decoction in 16.1% (9/56) of trials; 26.8% (15/56) of trials did not reported information on this issue. It seemed that there was some inconsistency of dosages in clinical research when comparing granules and decoctions concurrently that raises additional questions about the rigor and validity of these findings. However trials that used a lower dose for granules than decoction also reported equivalent clinical outcomes for the two approaches. In addition, in 9 trials, granules were manufactured by the hospitals themselves without any details on preparation, which were questionable. Such heterogeneities should be avoided in future trials.

4.2.5. Inconsistency of prescription methods among granules

As reported in Section 3.3.4, there was an inconsistency with respect to how the granules were formulated in the included trials (2 trials did not report on the preparation of granules, granules in 9 trials were derived from decoctions of standardized herbal formulae, 45 trials used granules comprising aggregated mixtures of different single herbal granules). In the trials that used mixtures of different single herbal granules prescriptions were individualized for each patient. Since there is currently no formal definition of 'granules for prescription' from the Chinese government's pharmacopoeia (SATCM of China Editorial Committee of Chinese Materia

Medica, 1999), we would encourage the next edition of the pharmacopoeia (in 2015) to add a general chapter on granules for prescription, so as to avoid this inconsistency.

4.3. Clinical implications for Chinese practitioners using Chinese herbal medicine granules

The data from this review suggests that the aggregated mixtures of different single herb granules were just as effective as the granules derived from decoctions of complex herbal formulae in their respective trials. This has significant clinical and research implications because the CM clinician could, without any diminution of therapeutic effect, individualize therapy by combining single herbal granules rather than using the fixed, generic formulae available via granules from complex decoctions. However, the poor methodological quality of these trials means that we should be very circumspect about how we interpret these data. Once again more rigorous research is required to confirm or refute these preliminary findings.

5. Conclusion and recommendations

There are a number of limitations within the data that forms the basis of this review. The main problems with the included studies were related to their scientific quality, design and reporting all of which may create bias. Our initial and tentative conclusions will certainly require further research involving better study design, methodology and transparency, in particular the use of non-inferiority or equivalence designs (Huang and Zhao, 2007). We also suggest that researchers must pay attention to the dose of granules and decoctions, improve the quality of trials, and report the study and its funding in the normal manner within a CONSORT statement (Moher et al., 2010).

The results of this review provide preliminary data suggesting that CHM granules may have the same effectiveness and safety as decoctions. However, the poor methodological quality of most of the included trials means that we are unable to reach a definitive conclusion that both Chinese herbal medicine granules and decoctions have the same degree of effectiveness and safety in clinical practice. We suggest that, subject to more and better research, studies should focus on using quality controlled granules manufactured by well regulated pharmaceutical companies to treat clearly defined syndromes or diseases. Comparisons of standardized vs individualized treatments, and aggregated granules vs granules derived from complex decoctions are important secondary questions for CHM that need to be addressed as a matter of some urgency.

Granular preparations can be recommended for clinical use as they are safe and certainly simpler to control, produce and manage as a consistent medical product than decoctions. If granules are to be used more widely in China, then pharmaceutical companies and hospitals must reduce their production and distribution costs to lower the price of granules and make them a more realistic and competitive option for clinicians and patients. Furthermore the government should consider including the use of granule based herbal preparations as part of Chinese medical health insurance if they wish them to be more widely used. In the West, granules are considerably cheaper to dispense than the dried herbs used for decoctions so these obstacles to the wider use of granules do not arise.

We believe this review provides a rational argument for the continued investigation and use of granules. They can provide a more consistent herbal product that will improve our ability to regulate and research Chinese Herbal Medicines internationally. We believe that further more rigorous and accurate pharmacological,

toxicological and clinical studies are required to confirm or refute these preliminary findings. It is only by clearly demonstrating equivalence that we can be certain of combining any therapeutic benefits from the long tradition of CHM with the practical advantages of more modern means of herbal medicine production.

Disclosure statement

The authors state that no competing financial interests exist in this systematic review.

Acknowledgements

The authors would like to thank Yihu Ni from University of Bergen, Norway for his suggestions on language. Guoyan Yang from Beijing University of Chinese Medicine for her assistance on designing the graphic abstract. Hui Luo, Qing Li and Jianping Liu were supported by a grant from international cooperation project (No. 2009DFA31460) from the Ministry of Science and Technology of China, and in part supported by the Basic Operational Funding for Scientific Research from Beijing University of Chinese Medicine.

References

- Bei, L.M., Xiong, Y.X., 2000. Comparison of effect between Chinese herbal medicine granules and decoction. *Yunnan Journal of Traditional Chinese Medicine and Materia Medica* 21, 31.
- 贝立民, 熊亚星, 2000. 中药免煎颗粒与水煎剂疗效对比观察. *云南中医中药杂志* 21, 31.
- Chen, L.H., Wang, Q., Liu, J.N., 2006. Simultaneous analysis of nine active components in Gegen Qinlian preparations by high-performance liquid chromatography with diode array detection. *Journal of Separation Science* 29, 2203–2210.
- Chen, R.F., Lin, Q.Y., Xu, Y.Z., et al., 2009. Clinical research on yiweisan granules for chronic gastritis. *Clinical Journal of Traditional Chinese Medicine* 21, 295–296.
- 陈瑞发, 林启有, 许永周, et al., 2009. 益胃散颗粒治疗慢性胃炎临床研究报告. *中医药临床杂志* 21, 295–296.
- Cheng, H., 2000. Scientific and cost-effect analysis of granules. *Capital Medicine* 7, 29–31.
- 程宏, 2000. 免煎中药饮片剂型的科学性及其成本-效益分析. *首都医药* 7, 29–31.
- Cheng, X.R., Zhu, Y., 1999. Clinical study of treatment of stomach pain (qi stagnation syndrome) with chaihui shugansan granules. *Chinese Journal of Primary Medicine and Pharmacy* 6, 346.
- 程学仁, 朱炎, 1999. 柴胡疏肝散单味中药浓缩颗粒组方治疗胃脘痛(气滞证)的临床观察. *中国基层医药* 6, 346.
- Du, S.H., Xie, Z.M., 1998. Comparison of effect among extract granules, decoction and tablets of yinqiao san. *Chinese Journal of Information on Traditional Chinese Medicine* 5, 32.
- 杜少辉, 谢志敏, 1998. 银翘散浸膏颗粒剂与汤剂, 片剂的临床疗效对比观察. *中国中医药信息杂志* 5, 32.
- Edwin Lowell, C., Nobuo, Y., 2004. *Complementary and Alternative Approaches to Biomedicine*. Kluwer Academic/Plenum Publishers, New York, USA, pp. 27–28.
- Feng, L., Fang, L.P., Cong, P., 2005. Comparison of clinical effect between bazhengsan granules and decoction. *Fujian Journal of Traditional Chinese Medicine* 36, 39–40.
- 冯璐, 房莉萍, 从鹏, 2005. 八正散单味浓缩颗粒剂与合煎汤剂的疗效对比观察. *福建中医药* 36, 39–40.
- Gao, H., Zhou, D.Q., Zheng, X.Y., et al., 1998. Comparison of effect between extract granules and decoction for acute hepatitis E. *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases* 8, 84.
- 高辉, 周大桥, 郑晓英, et al., 1998. 浸膏颗粒剂与汤剂治疗急性戊型肝炎的对比分析. *中西医结合肝病杂志* 8, 84.
- Guo, H., Zhao, Z.Y., 2004. Comparison of effect between dancao decoction and granules for herpes zoster. *Tianjin Medical Journal* 32, 244–245.
- 郭浩, 赵振宇, 2004. 胆草煎剂与颗粒剂治疗带状疱疹的对比观察. *天津医药* 32, 244–245.
- Higgins, J.P.T., Green, S., 2009. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2*. The Cochrane Collaboration.
- Hu, S.R., Wang, H.J., 2000. Comparison of effect between granules and decoction on the treatment of difficult diseases. *Chinese Journal of Experimental Traditional Medical Formulae* 6, 53–55.
- 胡思荣, 王洪军, 2000. 免煎中药颗粒剂与自煎中药汤剂治疗疑难杂症临床疗效比较. *中国实验方剂学杂志* 6, 53–55.
- Hu, B.L., Zeng, X.J., 2000. Clinical observation between xiaochaihu tang granules and decoction. *New Journal of Traditional Chinese Medicine* 32, 38–39.
- 胡标伦, 曾宪进, 2000. 小柴胡汤单煎与合煎的临床对比观察. *新中医* 32, 38–39.
- Huang, Q., Zhao, M., 2007. Considerations on the statistical hypothesis of non-inferiority, equivalence and superiority design in clinical trial. *The Chinese Journal of Clinical Pharmacology* 23, 63–67.
- 黄钦, 赵明, 2007. 对临床试验统计学假设检验中非劣效、等效和优效性设计的认识. *中国临床药理学杂志* 23, 63–67.
- Huang, Y.J., Zhu, Q.Y., 2009. Comparison of Qingjin tangjiang decoction and granules for acute and chronic bronchitis (phlegm and heat syndrome). *Yunnan Journal of Traditional Chinese Medicine and Materia Medica* 30, 12–13.
- 黄雅菊, 朱启勇, 2009. 清金糖浆配方颗粒与饮片汤剂治疗慢性支气管炎(痰热证)的临床研究. *云南中医中药杂志* 30, 12–13.
- Jia, W., Zhang, L., 2005. Challenges and opportunities in the Chinese Herbal Drug Industry. *Natural Products*, 229–250.
- Kuang, L., Han, Y.G., Liu, X., 2008. Curative effects of Longdan xiegan granule on treatment of damp-heat genital herpes. *Journal of Traditional Chinese Medicine University of Hunan* 28, 68–70.
- 匡琳, 韩英光, 刘翔, 2008. 龙胆泻肝散配方颗粒治疗湿热型生殖器疱疹的临床观察. *湖南中医药大学学报* 28, 68–70.
- Li, A.H., 2003. Comparison of effect between chaige yinqiaosan granules and decoction on the treatment of exogenous wind-heat syndrome patients. *Journal of Chinese Medicinal Materials* 26, 78.
- 李爱华, 2003. 柴葛银翘散颗粒剂与汤剂治疗外感风热证临床观察. *中药材* 26, 78.
- Li, Q., 2006. Chromatistics and prospects of single concentrated Chinese herbal medicine granules. *Lishizhen Medicine and Materia Medica Research* 17, 2006–2007.
- 李芹, 2006. 单味中药浓缩颗粒的特点及发展前景分析. *时珍国医国药* 17, 2006–2007.
- Li, A.J., Chen, X., 2010. People's doubt on TCM granules. *Capital Medicine* 1, 28–29.
- 李爱君, 陈曦, 2010. 人们对中药配方颗粒剂的“疑惑”. *首都医药* 1, 28–29.
- Li, C.H., Song, G.Y., Li, J.K., et al., 1999. preparation and clinical study of xiaoqinglong tang granules. *Chinese Journal of Hospital Pharmacy* 19, 247.
- 李春花, 宋国英, 李金科, et al., 1999. 小青龙(汤)冲剂的制备与临床疗效观察. *中国医院药学杂志* 19, 247.
- Li, C., Zhang, F., Chen, S.F., et al., 2008. Clinical trial of Sanjiu granules for infantile anorexia (spleen-stomach disharmony type). *Hubei Journal of Traditional Chinese Medicine* 30, 35–36.
- 李陈, 张凡, 陈淑芬, et al., 2008. 三九免煎颗粒治疗脾胃不和型小儿厌食症的临床研究. *湖北中医杂志* 30, 35–36.
- Liang, Q.H., Li, X.Q., 1995. Comparison between nao yi-an granule and decoction for their efficacy on acute cerebral hemorrhage of gan yang hua feng. *Journal of Hunan Medical University* 20, 215–218.
- 梁清华, 黎杏群, 1995. 脑溢安颗粒剂与汤剂治疗肝阳化风型急性脑出血临床疗效比较. *湖南医科大学学报* 20, 215–218.
- Liao, L.Y., Cai, X.G., Liu, B.Y., 2009. Comparison of Buyang Huanwu decoction ultrafine particle and traditional standards for stroke recovery with qi deficiency and blood stasis. *Journal of Traditional Chinese Medicine University of Hunan* 29, 50–52.
- 廖亮英, 蔡光先, 刘柏炎, 2009. 补阳还五汤超微颗粒与传统汤剂治疗中风恢复期气虚血瘀证的比较研究. *湖南中医药大学学报* 29, 50–52.
- Lin, X.R., Tu, C.X., Yang, C.M., et al., 2001. Clinical observation of fufang fuling decoction and granules for eczema. *Chinese Journal of Dermatology* 34, 66.
- 林熙然, 涂彩霞, 杨春梅, et al., 2001. 复方茯苓汤及冲剂治疗湿疹的临床疗效观察. *中华皮肤科杂志* 34, 66.
- Liu, J.P., 2009. *Clinical Research Methodology for Evidence-based Chinese Medicine*. People's Medical Publishing House, Beijing.
- 刘建平, 主编, 2009. *循证中医药临床研究方法*. 人民卫生出版社, 北京.
- Liu, K.J., 2008. Discussion of Chinese medicine decoction and granules. *Chinese Journal of Information on Traditional Chinese Medicine* 15, 106–107.
- 刘克敬, 2008. 浅谈传统中药汤剂与中药配方颗粒. *中国中医药信息杂志* 15, 106–107.
- Liu, J.H., Sun, H., Fa, Y.Y., 2005. Comparison of effect between xinjiang lithospermum granules and decoction for medical abortion. *Journal of Reproduction and Contraception* 25, 37–40.
- 刘建华, 孙桦, 法钰玉, 2005. 新疆紫草颗粒剂与汤剂对药物流产效果影响的比较性研究. *生殖与避孕* 25, 37–40.
- Ltd Jiangyin Tianjiang Pharmaceutical Co., 2011. Products of Granules. Online at: <http://www.tianjiang.com/en/product.htm>.
- Lu, M., Tian, Y.Z., Xia, J.Q., et al., 2008. Clinical study on drug granules of Huoxiang-Zhengqisan for the treatment of cold wetness diarrhea. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 14, 7–9.
- 陆敏, 田耀洲, 夏军权, et al., 2008. 藿香正气散中药配方颗粒治疗寒湿泄泻的临床研究. *中医药导报* 14, 7–9.
- Lv, C.S., Chen, B., Cai, G.X., et al., 2007. Comparison of the effect of oral ultra micro-granules and rhei decoction in retention enema on hepatopathy end toxemia at final stage. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 13, 35–37.
- 吕长生, 陈斌, 蔡光先, et al., 2007. 大黄煎剂超微配方颗粒与汤剂保留灌肠治疗终末期肝病内毒素血症的比较研究. *中医药导报* 13, 35–37.
- Lv, Z.H., Wen, Z.J., Qiu, J.M., et al., 2003. Clinical observation of jiawei bushen zhuangjin granules on the treatment of primary osteoporosis. *Journal of Hubei College of TCM* 5, 46–47.
- 吕朝晖, 温振杰, 邱剑鸣, et al., 2003. 加味补肾壮筋汤颗粒剂治疗原发性骨质疏松症的临床观察. *湖北中医学院学报* 5, 46–47.
- Ma, Y.P., Liu, X.Q., Chen, F.K., 2006. Comparison of Xiexintang dispensing granules and standard decoction with 3D-HPLC fingerprint chromatogram. *Chinese Traditional Patient Medicine* 28, 317–321.
- 马跃平, 刘晓秋, 陈发奎, 2006. 泻心汤配方颗粒与标准汤剂的HPLC指纹图谱对照研究. *中成药* 28, 317–321.

- Moher, D., Hopewell, S., Schulz, K.F., et al., 2010. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *PLoS Medicine* 7 (3), e1000251.
- Pan, P.G., Pan, B.Q., Pei, Z.A., et al., 2005. Clinical observation on 103 cases of chronic prostatitis treated by qianlie-an series formula enema. *New Journal of Traditional Chinese Medicine* 37, 46–47.
- 潘佩光, 潘奔前, 裴振安, et al., 2005. 前列安系列方灌肠治疗慢性前列腺炎103例疗效观察. *新中医* 37, 46–47.
- Peng, L.S., Zhou, D.Q., Gao, H., et al., 2003. Compare study on two types of jiagan mixture on treating viral hepatitis A. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 9, 18–19.
- 彭立生, 周大桥, 高辉, et al., 2003. 甲肝合剂两种剂型治疗甲型肝炎比较研究. *湖南中医药学报* 9, 18–19.
- Qi, D.M., Sun, Y.X., Yan, Q., et al., 1999. Clinical study of the treatment of some commonly encountered internal diseases with refined granules made from Chinese herbal pieces. *Lishizhen Medicine and Materia Medica Research* 10, 206–207.
- 齐冬梅, 孙英新, 闫琴, et al., 1999. 中药饮片精制颗粒免煎剂治疗几种内科常见病临床研究. *时珍国医国药* 10, 206–207.
- Qian, S.Y., Zhang, B., Huang, G.X., et al., 2003. Clinical observation of shengxuefang decoction and granules on the treatment of post-chemotherapeutic leukopenia. *Liaoning Journal of Traditional Chinese Medicine* 30, 651.
- 钱穗毅, 张蓓, 黄国贤, et al., 2003. 升血方汤剂与单煎颗粒防治化疗后白细胞降低的临床观察. *辽宁中医杂志* 30, 651.
- Qin, F.L., 2010. The clinical effects comparison of Tianmagoutengyin and Tianmagouteng particle on treating hypertension. *Chinese Journal of Modern Drug Application* 17, 72–73.
- 秦风莲, 2010. 天麻钩藤颗粒与天麻钩藤汤干预原发性高血压临床效果比较. *中国当代医药* 17, 72–73.
- Qiu, M., Zhou, D.Q., Zhou, X.Z., et al., 1998. Clinical study of yigan sanhao extract granules on the treatment of chronic hepatitis B. *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases*, 98–100.
- 邱梅, 周大桥, 周小舟, et al., 1998. 乙肝三号浸膏颗粒剂治疗慢性乙型肝炎病毒性肝炎临床研究. *中西医结合肝病杂志*, 98–100.
- SATCM of China Editorial Committee of Chinese Materia Medica, 1999. *Chinese Materia Medica*. Shanghai Scientific and Technical Publishers, Shanghai, p. 204.
- 国家中医药管理局中华本草编委会, 1999. 中华本草1. 上海科学技术出版社, 上海, p. 204.
- Shao, M., 1996. Clinical study of single herb formula chaihushugan yin for stomach pain of qi stagnation. *Journal of Jiangsu traditional Chinese Medicine* 17, 8–9.
- 邵锐, 1996. 单味中药饮片精制颗粒配方柴胡疏肝饮治疗气滞胃痛临床报告. *江苏中医* 17, 8–9.
- Sun, R.Z., 2004. Clinical Observation of kangyinfang on the treatment of 139 cases of psoriasis vulgaris. *New Journal of Traditional Chinese Medicine* 36, 44–45.
- 孙瑞珍, 2004. 抗银方治疗寻常型银屑病139例疗效观察. *新中医* 36, 44–45.
- Sun, W.F., Xu, W., Yao, F.Q., et al., 2003. Therapeutic effect of xiezhuo chubi decoction on primary gout hyperuricemia. *Hebei Journal of Traditional Chinese Medicine* 25, 13–14.
- 孙维峰, 徐伟, 姚富庆, et al., 2003. 泄浊除痹汤治疗原发性痛风尿酸血症疗效观察. *河北中医* 25, 13–14.
- Tan, B.S., Tan, D.G., 2010. Cost-effect analysis of Chinese medicine granules and decoction. *China's Naturopathy* 18, 59–60.
- 谭伯森, 谭大刚, 2010. 中药配方颗粒与中药饮片的成本及效果分析. *中国民间疗法* 18, 59–60.
- Tian, D.Y., Hu, N.W., Jiang, Y., 1985. Clinical observation of different formulations of Chinese herbal medicine on 167 cases of stomach pain. *Liaoning Journal of Traditional Chinese Medicine*, 32–34.
- 田德荫, 胡乃文, 姜颖, 1985. 应用不同剂型(冲、汤剂)治疗胃痛疗效观察——附167例病例分析. *辽宁中医杂志*, 32–34.
- Wang, P.J., Tao, D.S., Sun, Z.S., et al., 2009. Clinical observation on 26 cases of papular urticaria treated by funing granules. *Jiangsu Journal of Traditional Chinese Medicine* 41, 45–46.
- 王佩娟, 陶迪生, 孙兆圣, et al., 2009. 肤宁冲剂免煎配方颗粒治疗丘疹性荨麻疹26例临床观察. *江苏中医药* 41, 45–46.
- Wang, Y.S., Yuan, Z.R., Zhou, J.L., 1998. Clinical study of fine granules of huoxiang zhengqi san on 60 cases of cold, vomiting and diarrhea. *Information on Traditional Chinese Medicine*, 28–29.
- 王永山, 袁铸人, 周嘉琳, 1998. 饮片精制颗粒配方藿香正气散治疗感冒、呕吐、泄泻60例临床观察. *中医药信息*, 28–29.
- Wei, L.B., Zhang, Y., Wang, N.H., 2009a. Clinical study on Shenshui Yangzhen granule in improving malnutrition complicated by the chronic kidney disease period of four or five. *Chinese Journal of Integrated Traditional and Western Nephrology* 10, 696–699.
- 魏连波, 张颖, 汪南海, 2009. 肾衰养真颗粒治疗慢性肾脏病4、5期并发营养不良的临床观察. *中国中西医结合肾病杂志* 10, 696–699.
- Wei, L.F., Tian, Y.Z., Xia, J.Q., et al., 2009b. Comparison of Liangfu wan decoction and granules for stomach pain. *Lishizhen Medicine and Materia Medica Research* 20, 612–614.
- 魏兰福, 田耀洲, 夏军权, et al., 2009. 良附丸中药配方颗粒与饮片汤剂治疗胃痛临床对比研究. *时珍国医国药* 20, 612–614.
- Xia, J.G., 2000. Discussion of concentrated Chinese herbal medicine granules and decoction. *Lishizhen Medicine and Materia Medica Research* 11, 130.
- 夏金根, 2000. 浅谈中药饮片浓缩颗粒与中药汤剂. *时珍国医国药* 11, 130.
- Xiang, L.L., Zhang, Y.C., Li, H.J., et al., 2009. Comparison of cooling blood and detoxifying Chinese herbal medicine decoction and granules for chronic hepatitis B. *New Journal of Traditional Chinese Medicine* 41, 23–24.
- 向莉琳, 张云城, 李慧涓, et al., 2009. 凉血解毒中药汤剂与颗粒剂治疗慢性乙型肝炎疗效比较研究. *新中医* 41, 23–24.
- Xie, S., Li, J.J., 2010. Effect of Four Miraculous herbs decoction ultrafine particle in retention enema on 58 cases of ulcerative colitis with Yang deficiency of spleen and kidney. *Chinese Medicine Modern Distance Education of China* 8, 17–19.
- 谢硕, 李建军, 2010. 四神丸超微颗粒剂保留灌肠治疗中度溃疡性结肠炎脾胃阳虚证58例. *中国中医药现代远程教育* 8, 17–19.
- Xu, X.Y., 1980. Clinical analysis of 135 cases of rheumatoid arthritis treated by riptyerygium. *People's Military Surgeon*, 38–41.
- 徐夏英, 1980. 雷公藤治疗类风湿性关节炎135例疗效分析. *人民军医*, 38–41.
- Xu, J.L., Zhang, C.G., Liu, G.N., 1998. Granules, decoction and pills of buzhang yiqi tang for peptic ulcer and chronic gastritis: a clinical study. *Pharmacology and Clinics of Chinese Materia Medica* 14, 42.
- 许家骊, 张诚光, 刘广南, 1998. 补中益气颗粒剂、汤剂和丸剂对消化性溃疡、慢性胃炎临床疗效观察. *中药药理与临床* 14, 42.
- Yang, J.F., Liu, Y.L., 2007. Comparison of self-made decoction and granules for sinusitis. *Guangxi Journal of Traditional Chinese Medicine* 30, 55.
- 杨家福, 刘永琳, 2007. 颗粒剂自拟鼻窦炎处方与饮片水煎剂临床疗效对照. *广西中医药* 30, 55.
- Yang, H., Tian, L.J., Geng, Y.H., et al., 2008. Effect of Yiqizhuyu decoction on uterine myoma peri-menopausal period. *Hebei Journal of Traditional Chinese Medicine* 30, 686–688.
- 杨慧, 田李军, 耿永红, et al., 2008. 益气逐瘀汤治疗围绝经期子宫肌瘤疗效观察. *河北中医* 30, 686–688.
- Yang, J.M., Wang, M.X., Zhu, F.S., 2010. Comparison of the efficacy between different forms of Yiwei huacai drug on chronic atrophic gastritis. *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine* 20, 597–598.
- 杨剑明, 王慕曦, 朱方石, 2010. 益胃化裁方免煎颗粒与汤剂治疗慢性萎缩性胃炎疗效观察. *浙江中西医结合杂志* 20, 597–598.
- Yu, L.N., Xu, X.F., Shao, S.S., et al., 2010. Comparison of effect between decoction and granules. *Journal of Changchun College of Traditional Chinese Medicine* 26, 784–786.
- 俞路宁, 徐筱芳, 邵深深, et al., 2010. 传统煎法中药与免煎颗粒比较. *长春中医药大学学报* 26, 784–786.
- Yu, Y.L., Liu, S.H., Hu, X.Y., 2002. Comparison of effect between xiangsha liujunzi tang decoction and granules for deficiency of spleen qi. *Practical Clinical Medicine* 16, 14–15.
- 余永林, 刘胜红, 胡锡元, 2002. 香砂六君子汤颗粒剂与汤剂治疗脾气虚证疗效比较. *实用临床医学* 16, 14–15.
- Yuan, S.T., 1999. Thinking of single concentrated Chinese herbal medicine granules. *Research & Information on Traditional Chinese Medicine*, 25–26.
- 原思通, 1999. 对“单味中药浓缩颗粒”的思考. *中药研究与信息*, 25–26.
- Zeng, R., Zhu, Y.J., Yu, M.W., et al., 2006. Comparison of the effect of granules and decoction of xiaoqinglong tang. *Journal of Emergency in Traditional Chinese Medicine* 15, 1233–1234.
- 曾锐, 祝勇军, 俞脉文, et al., 2006. 小青龙汤单味浓缩配方颗粒与传统饮片临床疗效对比研究. *中国中医急症* 15, 1233–1234.
- Zhai, H., 2003. Comparison of effect between granules and decoction on the treatment of wind-heat cold. *Hubei Journal of Traditional Chinese Medicine* 25, 28.
- 翟洪, 2003. 中药颗粒剂与饮片治疗风热感冒的疗效比较. *湖北中医杂志* 25, 28.
- Zhang, D.A., 1998. Comparison of effect between lidan tongfutang decoction and granules on the treatment of non-acute cholecystitis. *Pharmacology and Clinics of Chinese Materia Medica* 14, 47–48.
- 张殿安, 1998. 利胆通腑汤煎剂与颗粒剂治疗非急性期胆囊炎的临床疗效观察. *中药药理与临床* 14, 47–48.
- Zhang, D.A., Huang, A.J., 1996. Comparison of huoxiang zhengqi san decoction and granules for damp stagnation. *Journal of Zhejiang Traditional Chinese Medicine* 31, 402.
- 张殿安, 黄爱娟, 1996. 藿香正气散煎剂与颗粒剂治疗湿阻的临床疗效观察. *浙江中医杂志* 31, 402.
- Zhang, X.X., Jiang, Z.Y., 2005. Advantage and disadvantage of Chinese medicine granules. *Chinese Archives of Traditional Chinese Medicine* 23, 1116–1117.
- 张筱霞, 江照云, 2005. 中药单煎颗粒剂利弊的分析. *中医药学刊* 23, 1116–1117.
- Zhang, X.Y., Cai, P.P., 2009. Clinical observation of different formulation of modified Qianjin weijing decoction on acute sinusitis. *Chinese Journal of Information on Traditional Chinese Medicine* 16, 73.
- 张小艺, 蔡平平, 2009. 加味千金苇茎汤不同剂型治疗急性鼻窦炎的临床观察. *中国中医药信息杂志* 16, 73.
- Zhang, B.G., Wang, X.L., Liu, Q.F., 2000. Current status and development of Chinese herbal medicine granules. *Chinese Pharmaceutical Journal* 35, 487–489.
- 张保国, 王学礼, 刘庆芳, 2000. 中药颗粒剂研究的现状与发展动态. *中国药学杂志* 35, 487–489.
- Zhang, B.Z., Huang, C.L., Zhou, X.B., et al., 2006. Clinical research of 4 formulations of zhigancao tang for angina pectoris (type of deficiency of qi and yin). *Chinese Journal of Experimental Traditional Medical Formulae* 12, 64–65.
- 张本页, 黄春玲, 周小波, et al., 2006. 4种方法制取炙甘草汤方治疗气阴两虚型冠心病心绞痛的研究. *中国实验方剂学杂志* 12, 64–65.
- Zhang, X.M., Jiang, L.D., Shang, X.Z., et al., 2002. Comparison of effect between chaihuguizhi tang decoction and granules on the treatment of influenza. *Journal of Emergency in Traditional Chinese Medicine* 11, 174–175.
- 张晓梅, 姜良铎, 商学征, et al., 2002. 柴胡桂枝汤加味方汤剂与颗粒剂治疗流行性感冒疗效对比研究. *中国中医急症* 11, 174–175.
- Zhao, C.L., 1996. Discussion on the alternatives of decoction to granules. *Jiangsu Pharmaceutical and Clinical Research* 4, 72–74.
- 赵成林, 1996. 中药单煎颗粒剂混合冲服替代汤剂的商榷. *江苏药学与临床研究* 4, 72–74.

- Zhao, L., Li, A.Y., Qi, F.H., 2009. Clinical study of sangke granules on 50 cases of acute bronchitis children. *Journal of Zhejiang University of Traditional Chinese Medicine* 33, 774–776.
- 赵林, 李安源, 齐芳华, 2009. 桑咳颗粒治疗小儿急性支气管炎50例临床观察. *浙江中医药大学学报* 33, 774, 776.
- Zhou, B., Tian, Y.P., Sun, G.P., 2009. Comparison of Chinese herbal medicine decoction and granules for pelvic inflammation. *Modern Journal of Integrated Traditional Chinese and Western Medicine* 18, 4369–4370.
- 周赟, 田亦平, 孙桂萍, 2009. 中药颗粒免煎剂与传统煎剂用于妇科盆腔炎症疗效比较. *现代中西医结合杂志* 18, 4369-4370
- Zhou, C.Y., Zhang, P., Fan, B., et al., 1999. Clinical investigation on effect of xiaobiling medicine tea bag on tetanic rachitis. *Chinese Traditional Patent Medicine* 21, 299–302.
- 周翠英, 张鹏, 樊冰, et al., 1999. 消痹灵袋泡剂治疗强直性脊柱炎的临床研究. *中成药* 21, 299-302.
- Zhou, P., Liu, W., Wang, S.L., 2008. Clinical observation on 36 cases of insomnia treated by Qingre huatan anshen granules. *Journal of Sichuan of Traditional Medicine* 26, 68–69.
- 周萍, 刘伟, 王松龄, 2008. 清热化痰安神颗粒治疗失眠36例临床观察. *四川中医* 26, 68-69.
- Zhu, X.Y., He, S.Z., Xu, K.J., et al., 1995. Comparison of liuweidihuang decoction, granules, and pills on the effect and change of blood indexes of yin deficiency of kidney patients. *Pharmacology and Clinics of Chinese Materia Medica*, 44–46.
- 朱秀英, 何树庄, 徐凯建, et al., 1995. 六味地黄冲剂与六味地黄汤、丸剂对肾阴虚病人血液中部分指标及临床疗效的对比研究. *中药药理与临床*, 44-46.